Szczegóły obiektu: Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Instytucja dostarczająca:Repozytorium Uniwersytetu Łódzkiego

Opis

Tytuł:
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)
Twórca:
Rogalska, Aneta
Współtwórca:
Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236, Lodz, Poland.;
aneta.rogalska@biol.uni.lodz.pl
Opis:
Resistance to olaparib inevitably develops in ovarian cancer (OC) patients, highlighting the necessity for effective strategies to improve its efficacy. Here, we established a novel olaparib-resistant patient-derived xenograft model of high-grade serous OC with BRCA1/2 mutations and examined the molecular characteristics of acquired resistance and resensitization to olaparib in treatment-naïve tumors in vivo. Olaparib-resistant xenografts were treated with olaparib, ATR inhibitor (ATRi, ceralasertib), CHK1 inhibitor (CHK1i, MK-8776) or their combinations. Proliferation, apoptosis, ATR/CHK1 activity, PARP signaling, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and MDR1 expression, were examined via RT-qPCR, western blot, and immunohistochemistry. Resistant tumors exhibited defects in PARP and ATR/CHK1 signaling, accompanied by altered expression of proteins involved in DDR and EMT. Olaparib rechallenge combined with ATR/CHK1 inhibitors showed promising synergistic effects on tumor growth inhibition. Mechanistically, combined treatments suppressed tumor proliferation without increasing apoptosis or necrosis, while inducing tumor cell vacuolization indicative of cell death. ATRi combined with olaparib induced or augmented downregulation of ATR, CHK1, PARP1, PARG, BRCA1, γH2AX, and PARylated protein expression, while reversing olaparib-induced upregulation of vimentin, BRCA2, and 53BP1. Our collective findings indicate that ATR/CHK1 pathway inhibition restores the olaparib efficacy in resistant BRCA1/2MUT high-grade serous OC, highlighting promising approach for olaparib rechallenge of non-responsive patients. Uncovered mechanisms might improve our understanding of acquisition and overcoming resistance to olaparib in ovarian cancer.;
National Science Centre, Poland (Project grant number: Sonata Bis 2019/34/E/NZ7/00056).
Dostępność obiektu:
Dostęp otwarty
Prawa:
CC0 1.0 uniwersalna;
http://creativecommons.org/publicdomain/zero/1.0
Data:
2025.01.27;
2024
Typ:
Dataset
Język:
angielski
Format:
application/octet-stream
Temat i słowa kluczowe:
ATR/CHK1 pathway;
Olaparib resistance;
Patient-derived xenograft;
Ovarian cancer;
Resensitization
Identyfikator: http://hdl.handle.net/11089/54405
Dostawca danych:
Repozytorium Uniwersytetu Łódzkiego

Podobne obiekty

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Twórca:Rogalska, Aneta

Data:2025.01.27 | 2024

Rodzaj zawartości:teksty

Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Twórca:Rogalska, Aneta

Data:2024.07.02 | 2024

Rodzaj zawartości:teksty

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Twórca:Rogalska, Aneta

Data:2023.04.11 | 2020.10.01

Rodzaj zawartości:teksty

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

Twórca:Biegała, Łukasz | Gajek, Arkadiusz | Marczak, Agnieszka | Rogalska, Aneta

Data:2023.05.08 | 2023

Rodzaj zawartości:obrazy

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell Lines

Twórca:Rogalska, Aneta

Data:2025.02.27 | 2025

Rodzaj zawartości:teksty

PARP Inhibitors in the Treatment of Ovarian Cancer: a review of the latest research

Twórca:Zuzak, Andrzej Paweł | Satora, Małgorzata | Cieślik-Porębska, Magdalena | Kułak, Krzysztof | Niewiadomska , Jagoda

Data:2025.02.21

Rodzaj zawartości:teksty

Endometriosis and ovarian cancer - what they have in common?

Data:2020.08.17

Rodzaj zawartości:teksty

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells, Sonata Bis 2019/34/E/NZ7/00056, Sonata Bis-9 (dataset)

Twórca:Rogalska, Aneta

Data:2024.03.07 | 2023

Rodzaj zawartości:teksty

Federacja Bibliotek Cyfrowych

Szczegóły obiektu: Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Opis

Podobne obiekty